# Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination.

> **NCT07444164** · PHASE1 · COMPLETED · sponsor: **Laboratorios Silanes S.A. de C.V.** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** A1: Ticagrelor / Acetylsalicylic acid in fixed dose combination capsule. (Laboratorios Silanes S.A. de C.V.)
- **DRUG:** A2: Ticagrelor (BRILINTA®, AstraZeneca S.A. de C.V.) A3: Acetylsalicylic Acid (ASPIRINA JUNIOR®, Bayer de México S.A. de C.V.)

## Key facts

- **NCT ID:** NCT07444164
- **Lead sponsor:** Laboratorios Silanes S.A. de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-13
- **Primary completion:** 2025-01-23
- **Final completion:** 2025-02-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07444164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07444164, "Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07444164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*